David Risinger

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Valeant Pharmaceuticals (NYSE: VRX), and raised the price target from $183.00 to $223.00. In the report, Morgan Stanley noted, "We estimate SLXP will be 20% accretive in 2016E, ramping to 37% in...

In a report published Wednesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), and raised the price target from $175.00 to $183.00. In the report, Morgan Stanley noted, “We are bumping our PT from $175 to $183, driven by...

In a note out Thursday, analyst David Risinger of Morgan Stanley lowered his rating on Bristol-Myers Squibb Co (NYSE: BMY) from Overweight to Equal-Weight, but maintained his $60 price objective. The change is attributed to the recent rally in the shares, with Bristol-Myers having rallied 17...

Morgan Stanley upgraded Zoetis Inc (NYSE: ZTS) from Underweight to Equal-Weight and raised its price target from $32 to $48 on Wednesday. The upgrade came after news that Pershing Square had acquired a stake in the company. Analysts led by David Risinger expected "Pershing Square to push...

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY). In the report, Morgan Stanley noted, “We think BMY stock could move up 10–15% to ~$57 on CheckMate 017 (squamous) success, and move...

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Actavis plc (NYSE: ACT), and raised the price target from $246.00 to $266.00. In the report, Morgan Stanley noted, “We believe more large-cap Value and GARP fund managers will come to appreciate...

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Alkermes plc (NASDAQ: ALKS). In the report, Morgan Stanley noted, “We reduced 2014E EPS from $0.52 to $0.30, near the upper end of management guidance of $0.19–0.32.The main driver was...

In a report published Wednesday, Morgan Stanley analyst David Risinger resumed coverage on Actavis plc (NYSE: ACT) with an Overweight rating and $246.00 price target. In the report, Morgan Stanley noted, “The Forest acquisition is financially compelling and sets the stage for more value-creating M...

In a report published Monday, Morgan Stanley analyst David Risinger reiterated an Underweight rating on Eli Lilly & Co. (NYSE: LLY), but removed the $48.00 price target. In the report, Morgan Stanley noted, “Ramu's survival benefit in 2nd-line lung cancer was below expectations and almost not...

In a report published Monday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Abbvie (NYSE: ABBV), but removed the $60.00 price target. In the report, Morgan Stanley noted, “Abbvie announced very encouraging new data on cancer candidates at ASCO. Abbvie presented...

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating and $19.00 price target on Phibro Animal Health Corp. (NASDAQ: PAHC). In the report, Morgan Stanley noted, “F3Q sales and EBITDA were as expected; EPS was above due to IPO/refinancing pro forma...

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Bristol-Myers Squibb (NYSE: BMY), but removed the $60.00 price target. In the report, Morgan Stanley noted, “We found the nivo (PD-1) + Yervoy combo lung cancer data disappointing, but hope for...

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Allergan (NYSE: AGN). In the report, Morgan Stanley noted, “Following AGN's rejection of VRX's bid and new guidance, we are raising ests and stand alone 1-yr base case from $125 to $164....

In a note released Wednesday, Morgan Stanley analyst David Risinger upgraded AbbVie (NYSE: ABBV) from Equal-weight to Overweight and raised the price target from $47 to $60. Risinger made it clear that the primary reason for this upgrade is AbbVie's hepatitis-C cure regimen which is set to launch...